13 Oct 2015 16:08
Premaitha Health PLC
Results of Annual General Meeting
Manchester, UK - 13 October 2015 - Premaitha Health PLC (AIM: NIPT, "Premaitha" or the "Company") announces that all resolutions proposed at the Annual General Meeting held today were duly passed.
-Ends-
For more information, please contact:
| |
Premaitha Health PLCDr Stephen Little, Chief Executive OfficerJoanne Cross, Marketing Communications
| Tel: +44 (0) 161 667 1053Email: investors@premaitha.com |
Cairn Financial Advisers LLP (NOMAD)Liam Murray / Avi Robinson
| Tel: +44 (0) 20 7148 7900 |
Panmure Gordon (UK) Limited (Broker)Robert Naylor (Corporate Finance) Maisie Atkinson (Corporate Broking)
| Tel: +44 (0) 20 7886 2714 Tel: +44 (0) 20 7886 2905 |
Instinctif PartnersMelanie Toyne Sewell / Jayne Crook / Emma Barlow | Tel: +44 (0) 207 457 2020 premaitha@instinctif.com |
Notes to Editors
About Premaitha Health
Premaitha is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha's flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.
The IONA® test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha's clinical laboratory customers to perform the test in their own facilities. This supports Premaitha's strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.
Premaitha is listed on the London Stock Exchange (AIM). Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK. For further information please visit www.premaitha.com or email iona@premaitha.com.
YGEN.L (YGEN)